ArticleInternational urogynecology journal2026
Impact of Intravesical Chondroitin Sulfate Instillation on Sexual Function in Women with Interstitial Cystitis/Bladder Pain Syndrome.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisSexual dysfunction is highly prevalent among women with interstitial cystitis/bladder pain syndrome (IC/BPS), yet evidence regarding the effects of intravesical therapies on sexual function remains limited. Intravesical chondroitin sulfate was used as a therapeutic option to alleviate symptoms of IC/BPS by restoring the glycosaminoglycan layer of the bladder. On the basis of previous clinical evidence, we hypothesized that intravesical chondroitin sulfate instillation would be associated with improvements in female sexual function and bladder-related symptoms in women with IC/BPS.
methodsThis single-center retrospective study analyzed prospectively collected data from sexually active women with IC/BPS who underwent intravesical chondroitin sulfate instillation between January 2023 and March 2025. Patients refractory to conservative and oral medical therapies were included. Sexual function was assessed using the Turkish validated version of the Female Sexual Function Index (FSFI). Bladder-related symptoms were evaluated using the Visual Analog Scale (VAS), Interstitial Cystitis Symptom Index (ICSI), and Interstitial Cystitis Problem Index (ICPI). Outcomes were compared between baseline and the 6-month follow-up.
resultsA total of 22 women were included in the analysis. The mean total FSFI score increased significantly from 16.22 ± 6.75 at baseline to 21.53 ± 7.11 at 6 months (p < 0.001). Significant improvements were observed in desire (p = 0.002), arousal (p = 0.010), lubrication (p = 0.001), orgasm (p < 0.001), satisfaction (p = 0.006), and pain (p = 0.002) after treatment. In parallel, bladder-related symptoms improved significantly, with reductions in VAS, ICSI, and ICPI scores at the 6-month follow-up.
conclusionsIntravesical chondroitin sulfate instillation was associated with significant improvements in sexual function and bladder-related symptoms in women with IC/BPS. These findings suggest that barrier-restoring intravesical therapy may represent a beneficial treatment option for addressing sexual dysfunction in this population.
Indexed as
Identifiers
41902922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.